drugset / Trial / NCT03757910
Brain Imaging in the Diabetes Prevention Program Outcomes Study
Phase 0
Terminated
5 enrolled
José A. Luchsinger
Albert Einstein College of Medicine · collabGeorge Washington University · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This is a cross-sectional pilot study of Alzheimer's disease (AD) brain imaging biomarkers in Diabetes Prevention Program (DPP) outcomes study (DPPOS) participants from the New York City sites (Columbia and Einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized to placebo in DPP. All study procedures will be conducted at Columbia University Irving Medical Center. Eligible participants will receive a PET scans and a brain MRI, which may be conducted in one, two, or three separate visits.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11C-PiB | Diagnostic / imaging agent | 185 mbq | Intravenous |
| Subject | 11C-PiB | Diagnostic / imaging agent | 555 mbq | Intravenous |
| Subject | 18F-MK-6240 | Diagnostic / imaging agent | 185 mbq | — |